Funding round brings in $75M for Ultragenyx

12/21/2012 | North Bay Business Journal (Santa Rosa, Calif.)

Ultragenyx Pharmaceutical secured $75 million in a Series B funding round and will use the money to further develop its lead drug candidates, UX001 and UX003. UX001 is being developed as a replacement therapy for hereditary inclusion body myopathy, while UX003 is an experimental enzyme replacement therapy for mucopolysaccharidosis type 7.

View Full Article in:

North Bay Business Journal (Santa Rosa, Calif.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA